HomeCompareETTX vs PLD

ETTX vs PLD: Dividend Comparison 2026

ETTX yields 91.32% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $3.19M in total portfolio value· pulled ahead in Year 10
10 years
ETTX
ETTX
● Live price
91.32%
Share price
$2.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.71M
Annual income
$860,660.59
Full ETTX calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ETTX vs PLD

📍 PLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETTXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETTX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETTX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX
Annual income on $10K today (after 15% tax)
$7,762.56/yr
After 10yr DRIP, annual income (after tax)
$731,561.50/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,306,554.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + PLD for your $10,000?

ETTX: 50%PLD: 50%
100% PLD50/50100% ETTX
Portfolio after 10yr
$4.31M
Annual income
$2,805,692.89/yr
Blended yield
65.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ETTX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys
0
PLD buys
0
No recent congressional trades found for ETTX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETTXPLD
Forward yield91.32%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$2.71M$5.91M
Annual income after 10y$860,660.59$4,750,725.19
Total dividends collected$2.40M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ETTX vs PLD ($10,000, DRIP)

YearETTX PortfolioETTX Income/yrPLD PortfolioPLD Income/yrGap
1$19,832$9,132.42$11,241$540.96+$8.6KETTX
2$38,148$16,926.92$13,019$991.13+$25.1KETTX
3$71,247$30,428.85$15,801$1,870.97+$55.4KETTX
4$129,347$53,112.88$20,609$3,701.21+$108.7KETTX
5$228,518$90,117.05$29,919$7,867.97+$198.6KETTX
6$393,309$148,794.86$50,631$18,617.74+$342.7KETTX
7$660,182$239,341.26$105,528$51,352.20+$554.7KETTX
8$1,081,855$375,459.71$287,364$174,449.42+$794.5KETTX
9$1,732,607$575,022.24$1,081,760$774,280.77+$650.8KETTX
10← crossover$2,714,550$860,660.59$5,908,209$4,750,725.19$3.19MPLD

ETTX vs PLD: Complete Analysis 2026

ETTXStock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ETTX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHDETTX vs JEPIETTX vs OETTX vs KOETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.